Genome Biologics1 applies their systematic discovery platform to develop their pipeline of new and repositioned drug candidates in cardiovascular, metabolic diseases, cancer and now COVID-19.
They use the AI-based GENIMAPS® computational platform to analyze massive data resources to identify non-obvious, mechanism-of-action based associations between compounds, molecular targets and diseases. They use this insight to find new uses for existing drugs or drug combinations, assess their risk profile, efficacy and function with their TrueCardium™ human cardiac organoid disease modeling and screening technologies, and their patented GENISYST® high-throughput in-vivo, in-situ platform – thus advancing them to PoC and Clinical Phases quicker, cheaper and with a higher probability of success than has been possible to date.
Genome Biologics is based in Frankfurt Germany and a resident company of Johnson & Johnson Innovation, JLABS @ BE.
 source: https://genomebiologics.com/